公开(公告)号：US20240423979A1

公开(公告)日：2024-12-26

申请号：US18703219

申请日：2022-10-20

Applicant: Hanmi Pharm. Co., Ltd.

Inventor： Ji Sook KIM ,  Jae Yul CHOI ,  Young Gil AHN

IPC: A61K31/506 ,  A61K31/635 ,  A61K31/706 ,  A61P35/02

Abstract: This invention relates to pharmaceutical compositions, pharmaceutical combinations and methods for the treatment of acute myeloid leukemia by combined use of a therapeutically effective combination of a compound of Chemical Formula 1, or a pharmaceutically acceptable salt thereof, solvate thereof, stereoisomer thereof, tautomer thereof, or combination thereof, wherein Ea, Eb, Ec, Ed, Z′, X′, Q, and k are defined herein; and a Bcl-2 inhibitor, or a Bcl-2 inhibitor and a hypomethylating agent.

公开(公告)号：US20240350590A1

公开(公告)日：2024-10-24

申请号：US18577592

申请日：2022-07-08

Applicant: HANMI PHARM. CO., LTD.

Inventor： Go-Wun CHOI ,  Hyuk-Jun CHO ,  Ho-Taek IM ,  Yong-ll KIM

IPC: A61K38/22 ,  A61K9/00 ,  A61K47/44

CPC classification number: A61K38/2278 ,  A61K9/0053 ,  A61K47/44

Abstract: A composition, suitable for an orally administered formulation, contains a GLP-1 analogue and, particularly, a hydrophobic ion-pair of a GLP-1 analogue and an oil phase. The pharmaceutical composition for oral administration forms an emulsion surrounding the hydrophobic ion-pair when exposed to a water phase, so as to be stably absorbed without being decomposed by digestive enzymes, and thus provides an effective and prolonged pharmacological effect. Methods for producing the composition for oral administration are also disclosed.

公开(公告)号：US20240293512A1

公开(公告)日：2024-09-05

申请号：US18565628

申请日：2022-06-30

Applicant: HANMI PHARM. CO., LTD.

Inventor： Jong Suk LEE ,  Yo Han KIM ,  Jung Kuk KIM ,  Sang Hyun LEE

IPC: A61K38/26 ,  A61K31/351 ,  A61K31/382 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K47/68 ,  A61P3/04 ,  A61P3/10

CPC classification number: A61K38/26 ,  A61K31/351 ,  A61K31/382 ,  A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61K47/6811 ,  A61K47/6889 ,  A61P3/04 ,  A61P3/10

Abstract: A combination including a peptide having activities to all of glucagon, GLP-1, and GIP receptors or a conjugate thereof; and an SGLT-2 inhibitor is disclosed. Uses of the combination are also disclosed. The combination is suitable for use in treating metabolic syndrome, liver disease, lung disease, or respiratory infections in a subject in need thereof.

公开(公告)号：US20230390362A1

公开(公告)日：2023-12-07

申请号：US18031958

申请日：2021-10-18

Applicant: HANMI PHARM. CO., LTD.

Inventor： Jong Suk LEE ,  Jung Kuk LEE ,  Seon Myeong LEE ,  Sang Hyun LEE ,  Jeong A KIM ,  Euh Lim OH ,  Chong Yoon LIM

IPC: A61K38/26 ,  A61K47/68 ,  A61P11/00

CPC classification number: A61K38/26 ,  A61K47/6811 ,  A61P11/00

Abstract: Provided is use of a trigonal agonist having activities to all of glucagon, GLP-1, and GIP receptors, and/or a conjugate thereof in the prevention or treatment of sequelae following respiratory infectious diseases.

公开(公告)号：US20230330184A1

公开(公告)日：2023-10-19

申请号：US18318492

申请日：2023-05-16

Applicant: Spectrum Pharmaceuticals Inc. ,  Hanmi Pharm Co., Ltd.

Inventor： Gajanan Bhat ,  Shanta Chawla ,  Jae Hyuk Choi ,  Eun jung Kim ,  Yu Yon Kim ,  Gyu Hyan Lee ,  Hyesun Han

IPC: A61K38/19 ,  C07K16/46 ,  A61K47/60

CPC classification number: A61K38/193 ,  C07K16/46 ,  A61K47/60 ,  C07K2317/53 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/522 ,  C07K2317/524

Abstract: This disclosure provides a method of preventing, alleviating or treating a condition (i.e., neutropenia) in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject. The method includes administering to the subject a therapeutically effective amount of a protein complex on the same day as a chemotherapy regimen, wherein the protein complex is a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

公开(公告)号：US20230310630A1

公开(公告)日：2023-10-05

申请号：US18016145

申请日：2021-07-16

Applicant: HANMI PHARM. CO., LTD.

Inventor： Jung Kuk KIM ,  Jong Suk LEE ,  Sang Hyun LEE ,  Euh Lim OH

IPC: A61K47/68 ,  A61K31/343 ,  A61K31/222

CPC classification number: A61K47/6811 ,  A61K31/222 ,  A61K31/343

Abstract: New therapeutic uses of a triple agonistic long-acting conjugate or a triple and a farnesoid X receptor (FXR) agonist, or a combination further containing an acetyl-CoA carboxylase (ACC) inhibitor are disclosed. The triple agonistic long-acting conjugate or a triple and a farnesoid X receptor (FXR) agonist, or a combination further containing an acetyl-CoA carboxylase (ACC) inhibitor, may be for preventing or treating a liver disease.

公开(公告)号：US20230248843A1

公开(公告)日：2023-08-10

申请号：US18304074

申请日：2023-04-20

Applicant: HANMI PHARM. CO., LTD.

Inventor： Cheongbyeol SHIN ,  Dooseo JANG ,  Ji Hye MOON ,  Dong Hyun KIM ,  Ji Eun LEE

IPC: A61K47/68 ,  A61K47/60 ,  A61K38/00 ,  C07K14/605

CPC classification number: A61K47/6811 ,  A61K47/60 ,  A61K38/00 ,  C07K14/605

Abstract: Provided is a novel method for preparing a long-acting drug conjugate and a long-acting drug conjugate prepared using the method.

公开(公告)号：US20230233567A1

公开(公告)日：2023-07-27

申请号：US17999799

申请日：2021-05-17

Applicant: Hanmi Pharm. Co., Ltd. ,  Genentech, Inc.

Inventor： Tae Won KIM ,  Yoon-hee HONG ,  Young Su NOH ,  Matthew Tsn-Wei CHANG ,  Shiva MALEK ,  Yibing YAN ,  Ivana Yen Yen YEN

IPC: A61K31/519 ,  A61P35/00 ,  A61P17/00

CPC classification number: A61K31/519 ,  A61P35/00 ,  A61P17/00

Abstract: Provided are methods for the use of belvarafenib to treat cancer having at least one mutation selected from a BRAFV600E mutation, a KRASG12V mutation, a KRASG12D mutation, a KRASG12C mutation, a KRASG12R mutation, a KRASG13D mutation, a KRASQ61H mutation, a NRASG12D mutation, a NRASG13D mutation, a NRASQ61K mutation, a NRASQ61L mutation, a NRASQ61R mutation, and a NRASG12C mutation.

公开(公告)号：US20230220034A1

公开(公告)日：2023-07-13

申请号：US17839053

申请日：2022-06-13

Applicant: HANMI PHARM. CO., LTD.

Inventor： Hyung Kyu LIM ,  Jong Soo LEE ,  Dae Jin KIM ,  Sung Min BAE ,  Sung Youb JUNG ,  Se Chang KWON

IPC: C07K14/605 ,  A61K38/28 ,  C07K14/62 ,  C07K1/107 ,  A61K38/29 ,  A61K38/26 ,  A61K9/08

CPC classification number: C07K14/605 ,  A61K38/28 ,  C07K14/62 ,  C07K1/1075 ,  A61K38/29 ,  A61K38/26 ,  A61K9/08 ,  C07K2319/00 ,  C07K2319/30

Abstract: A method for improving the solubility of a physiologically active protein or peptide compared to that of a physiologically active protein or peptide which is not conjugated to an immunoglobulin Fc fragment is disclosed. The method includes steps of conjugating the physiologically active protein or peptide to an immunoglobulin Fc fragment. Also disclosed is a composition for improving the solubility of a physiologically active protein or peptide, which contains an immunoglobulin Fc fragment. The composition improves the solubility compared to a composition without an immunoglobulin Fc fragment.

公开(公告)号：US20230210949A1

公开(公告)日：2023-07-06

申请号：US17927257

申请日：2021-05-24

Applicant: HANMI PHARM CO., LTD.

Inventor： Ji Hye MOON ,  Ji Eun LEE

IPC: A61K38/17 ,  A61K47/18 ,  A61K9/08 ,  A61K47/20 ,  A61K47/26 ,  A61K47/64 ,  A61K47/68

CPC classification number: A61K38/1796 ,  A61K47/183 ,  A61K9/08 ,  A61K47/20 ,  A61K47/26 ,  A61K47/64 ,  A61K47/68

Abstract: A liquid formulation of a long-acting conjugate of a peptide having activities for a glucagon receptor and a GLP-1 receptor, and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 940 nmol/mL of the long-acting conjugate, a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 4.5 to 7.5, and 1% (w/v) to 20% (w/v) of saccharide, and 0.001% (w/v) to 0.2% (w/v) of a nonionic surfactant.